Table 2.
Summary of total oral mucosal fluid collections from the vaccinated participants of the study.
| Participant | Age | Sex | Vaccine Manufacturer | Time Elapsed from 1st dose | Time points (Total) |
|---|---|---|---|---|---|
| S16 | 22 | F | N/A | 8 days | 9 |
| S35 | 56 | F | Pfizer | 9 days | 10 |
| S42 | 26 | F | Pfizer | 0 days | 7 |
| S44 | 66 | M | Pfizer | 6 days | 8 |
| S46 | 78 | M | Moderna | 32 days | 8 |
| S47 | 69 | F | Moderna | 18 days | 8 |
| S48 | 75 | F | Moderna | 34 days | 10 |
| S49 | 67 | F | Moderna | 37 days | 9 |
| S50 | 69 | F | Moderna | 28 days | 8 |
| S52 | 74 | M | Moderna | 44 days | 9 |
| S53 | 70 | F | Pfizer | 30 days | 7 |
| S54 | 71 | M | Pfizer | 30 days | 7 |
| S55 | 69 | M | Moderna | 39 days | 9 |
Vaccine manufacturer, time elapsed from their first dose to their maximum IgG concentration, as well as sex and age are described.
NA, not applicable.